View Future GrowtheXoZymes 過去の業績過去 基準チェック /06eXoZymesの収益は年平均-47.3%で減少しているが、Biotechs業界はgrowingで33.8%年平均の収益となった。主要情報-47.31%収益成長率-39.26%EPS成長率Biotechs 業界の成長17.04%収益成長率n/a株主資本利益率-632.98%ネット・マージンn/a前回の決算情報31 Mar 2026最近の業績更新お知らせ • Mar 26eXoZymes, Inc. to Report Q4, 2025 Results on Mar 31, 2026eXoZymes, Inc. announced that they will report Q4, 2025 results on Mar 31, 2026お知らせ • Mar 27eXoZymes, Inc. to Report Q4, 2024 Results on Apr 02, 2025eXoZymes, Inc. announced that they will report Q4, 2024 results on Apr 02, 2025すべての更新を表示Recent updatesお知らせ • Apr 10eXoZymes, Inc. has filed a Follow-on Equity Offering.eXoZymes, Inc. has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stockお知らせ • Mar 26eXoZymes, Inc. to Report Q4, 2025 Results on Mar 31, 2026eXoZymes, Inc. announced that they will report Q4, 2025 results on Mar 31, 2026New Risk • Dec 28New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$96.4m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$11m free cash flow). Earnings have declined by 51% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (US$96.4m market cap).分析記事 • Nov 13We Think eXoZymes (NASDAQ:EXOZ) Needs To Drive Business Growth CarefullyWe can readily understand why investors are attracted to unprofitable companies. For example, although...分析記事 • Jul 30We Think eXoZymes (NASDAQ:EXOZ) Needs To Drive Business Growth CarefullyThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...お知らせ • Jun 30+ 1 more updateeXoZymes, Inc.(NasdaqCM:EXOZ) dropped from Russell 3000E Value IndexeXoZymes, Inc.(NasdaqCM:EXOZ) dropped from Russell 3000E Value Indexお知らせ • Jun 23eXoZymes, Inc., Annual General Meeting, Jul 25, 2025eXoZymes, Inc., Annual General Meeting, Jul 25, 2025.New Risk • Jun 22New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$76.6m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$10m free cash flow). Earnings have declined by 52% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (16% average weekly change). Market cap is less than US$100m (US$76.6m market cap).お知らせ • Apr 11eXoZymes Inc. Announces Its Latest Initiative BioClickeXoZymes Inc. announced its latest initiative - BioClick - a pioneering concept designed to enhance and accelerate the engineering of enzymes for advanced chemical reactions. Funded in part by a $300K grant from the National Institutes of Health (NIH), this project has the potential to revolutionize how medicines and other bio-based compounds are created. At the heart of BioClick is a focus on group transfer reactions, a class of biochemical reactions that allow enzymes to precisely move small molecular chemical groups from one compound to another. Inspired by the 2022 Nobel Prize in Chemistry concept of Click Chemistry, often described as snapping LEGO pieces together, BioClick is now enabling new types of group transfers using custom enzymes. Among these, prenylation is a standout: a process where a small fatty molecular group is taken from a donor molecule and added to another drug compound to improve its function or how well it works in the body. This technique is especially promising in the development of more effective, targeted drugs and therapies, either as new drugs or as better versions of existing drugs. Critically, the BioClick tools also introduce new high-throughput screening capabilities, allowing researchers to test thousands of enzyme variations simultaneously. With the help of advanced tools like mass spectrometry and cutting-edge data analysis algorithms, eXoZymes can quickly identify which enzyme version works best for a given group transfer reaction - greatly enhancing the molecular level operation by quickly identifying the best-performing variants. This Artificial Evolution process dramatically reduces the time and cost required to develop the exozyme pathway that will produce a new or better drug.お知らせ • Apr 03eXoZymes Inc. Appoints Damien Perriman as Chief Commercial OfficereXoZymes Inc. announced the appointment of Damien Perriman to a newly created role as Chief Commercial Officer (CCO). Perriman brings more than two decades of experience in successfully commercializing several biotechnologies, spanning diverse markets such as nutrition, personal care, plastics, textiles, fragrances, performance fuels, and specialty chemicals. Before joining eXoZymes, Perriman most recently has served leading commercial roles at both Genomatica (Geno) and Gevo, while also serving as Chairman of the Board of Danish biotechnology startup Cellugy.New Risk • Mar 28New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$96.5m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.9m free cash flow). Negative equity (-US$3.6m). Revenue has declined by 101% over the past year. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (US$96.5m market cap).お知らせ • Mar 27eXoZymes, Inc. to Report Q4, 2024 Results on Apr 02, 2025eXoZymes, Inc. announced that they will report Q4, 2024 results on Apr 02, 2025お知らせ • Feb 23eXoZymes, Inc. Announces Management ChangesOn February 17, 2025, Mr. Mohammad Hayat, a member of the Board of Directors of eXoZymes Inc. as well as its President and Chairman of the Board, resigned from the Board and from all positions he held in the Company. On February 17, 2025, the Board appointed Mr. Edgardo Rayo as a member of the Board to fill the vacancy created by Mr. Hayat’s resignation. There is no current arrangement in place for compensation to Mr. Rayo as a director. The Board also appointed Mr. Christopher A. Marlett as the Chairman of the Board on the same date.New Risk • Jan 17New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$99.7m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.9m free cash flow). Negative equity (-US$3.6m). Revenue has declined by 101% over the past year. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (18% average weekly change). Market cap is less than US$100m (US$99.7m market cap).収支内訳eXoZymes の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史NasdaqCM:EXOZ 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Mar 260-106431 Dec 250-96430 Sep 250-86330 Jun 250-85331 Mar 250-75231 Dec 240-64230 Sep 240-53230 Jun 240-43131 Mar 240-32131 Dec 230-21130 Sep 230-11031 Dec 220-110質の高い収益: EXOZは現在利益が出ていません。利益率の向上: EXOZは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: EXOZは利益が出ておらず、過去 5 年間で損失は年間47.3%の割合で増加しています。成長の加速: EXOZの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: EXOZは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 43% ) と比較することは困難です。株主資本利益率高いROE: EXOZは現在利益が出ていないため、自己資本利益率 ( -632.98% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/26 03:05終値2026/05/26 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋eXoZymes, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Mar 26eXoZymes, Inc. to Report Q4, 2025 Results on Mar 31, 2026eXoZymes, Inc. announced that they will report Q4, 2025 results on Mar 31, 2026
お知らせ • Mar 27eXoZymes, Inc. to Report Q4, 2024 Results on Apr 02, 2025eXoZymes, Inc. announced that they will report Q4, 2024 results on Apr 02, 2025
お知らせ • Apr 10eXoZymes, Inc. has filed a Follow-on Equity Offering.eXoZymes, Inc. has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock
お知らせ • Mar 26eXoZymes, Inc. to Report Q4, 2025 Results on Mar 31, 2026eXoZymes, Inc. announced that they will report Q4, 2025 results on Mar 31, 2026
New Risk • Dec 28New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$96.4m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$11m free cash flow). Earnings have declined by 51% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (US$96.4m market cap).
分析記事 • Nov 13We Think eXoZymes (NASDAQ:EXOZ) Needs To Drive Business Growth CarefullyWe can readily understand why investors are attracted to unprofitable companies. For example, although...
分析記事 • Jul 30We Think eXoZymes (NASDAQ:EXOZ) Needs To Drive Business Growth CarefullyThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
お知らせ • Jun 30+ 1 more updateeXoZymes, Inc.(NasdaqCM:EXOZ) dropped from Russell 3000E Value IndexeXoZymes, Inc.(NasdaqCM:EXOZ) dropped from Russell 3000E Value Index
お知らせ • Jun 23eXoZymes, Inc., Annual General Meeting, Jul 25, 2025eXoZymes, Inc., Annual General Meeting, Jul 25, 2025.
New Risk • Jun 22New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$76.6m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$10m free cash flow). Earnings have declined by 52% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (16% average weekly change). Market cap is less than US$100m (US$76.6m market cap).
お知らせ • Apr 11eXoZymes Inc. Announces Its Latest Initiative BioClickeXoZymes Inc. announced its latest initiative - BioClick - a pioneering concept designed to enhance and accelerate the engineering of enzymes for advanced chemical reactions. Funded in part by a $300K grant from the National Institutes of Health (NIH), this project has the potential to revolutionize how medicines and other bio-based compounds are created. At the heart of BioClick is a focus on group transfer reactions, a class of biochemical reactions that allow enzymes to precisely move small molecular chemical groups from one compound to another. Inspired by the 2022 Nobel Prize in Chemistry concept of Click Chemistry, often described as snapping LEGO pieces together, BioClick is now enabling new types of group transfers using custom enzymes. Among these, prenylation is a standout: a process where a small fatty molecular group is taken from a donor molecule and added to another drug compound to improve its function or how well it works in the body. This technique is especially promising in the development of more effective, targeted drugs and therapies, either as new drugs or as better versions of existing drugs. Critically, the BioClick tools also introduce new high-throughput screening capabilities, allowing researchers to test thousands of enzyme variations simultaneously. With the help of advanced tools like mass spectrometry and cutting-edge data analysis algorithms, eXoZymes can quickly identify which enzyme version works best for a given group transfer reaction - greatly enhancing the molecular level operation by quickly identifying the best-performing variants. This Artificial Evolution process dramatically reduces the time and cost required to develop the exozyme pathway that will produce a new or better drug.
お知らせ • Apr 03eXoZymes Inc. Appoints Damien Perriman as Chief Commercial OfficereXoZymes Inc. announced the appointment of Damien Perriman to a newly created role as Chief Commercial Officer (CCO). Perriman brings more than two decades of experience in successfully commercializing several biotechnologies, spanning diverse markets such as nutrition, personal care, plastics, textiles, fragrances, performance fuels, and specialty chemicals. Before joining eXoZymes, Perriman most recently has served leading commercial roles at both Genomatica (Geno) and Gevo, while also serving as Chairman of the Board of Danish biotechnology startup Cellugy.
New Risk • Mar 28New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$96.5m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.9m free cash flow). Negative equity (-US$3.6m). Revenue has declined by 101% over the past year. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (US$96.5m market cap).
お知らせ • Mar 27eXoZymes, Inc. to Report Q4, 2024 Results on Apr 02, 2025eXoZymes, Inc. announced that they will report Q4, 2024 results on Apr 02, 2025
お知らせ • Feb 23eXoZymes, Inc. Announces Management ChangesOn February 17, 2025, Mr. Mohammad Hayat, a member of the Board of Directors of eXoZymes Inc. as well as its President and Chairman of the Board, resigned from the Board and from all positions he held in the Company. On February 17, 2025, the Board appointed Mr. Edgardo Rayo as a member of the Board to fill the vacancy created by Mr. Hayat’s resignation. There is no current arrangement in place for compensation to Mr. Rayo as a director. The Board also appointed Mr. Christopher A. Marlett as the Chairman of the Board on the same date.
New Risk • Jan 17New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$99.7m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.9m free cash flow). Negative equity (-US$3.6m). Revenue has declined by 101% over the past year. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (18% average weekly change). Market cap is less than US$100m (US$99.7m market cap).